Thyssenkrupp Nucera Forecasts Stable 2024/2025 Outlook Amid Market Challenges

Thyssenkrupp Nucera AG & Co. KGaA reported stable business development in the third quarter of 2024/2025. Preliminary figures indicate a EUR 63 million order intake and EUR 184 million in sales, though earnings before interest and taxes (EBIT) remained at zero. The company adjusted its revenue outlook, forecasting sales between EUR 850 million and EUR 920 million for the fiscal year.

The Green Hydrogen (gH2) segment saw sales of EUR 103 million, with EBIT improving from EUR –23 million to EUR –13 million. The Chlor-Alkali (CA) segment reported EUR 81 million in sales, with EBIT reaching EUR 13 million. Consolidated EBIT for the first nine months rose to an estimated EUR 4 million, improving year-over-year.

Given market hesitancy for green hydrogen investments, thyssenkrupp nucera refined its EBIT outlook. They anticipate consolidated EBIT between EUR –7 million and EUR 7 million. Dr. Stefan Hahn highlighted increased transparency from these updates, while CEO Dr. Werner Ponikwar emphasized expected order intake recovery.